Patents by Inventor Claas Junghans

Claas Junghans has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7915035
    Abstract: The invention concerns a vaccine that can induce protection against disease especially in consequence of a lentivirus infection, especially an infection with the Feline Leukosis virus. Such vaccine comprises codon-optimized DNA sequences encoding structural proteins and the most important membrane protein of FeLV.
    Type: Grant
    Filed: September 23, 2003
    Date of Patent: March 29, 2011
    Assignee: Mologen AG
    Inventors: Claas Junghans, Matthias Schroff, Christiane Juhls, Detlef Oswald, Hans Lutz
  • Publication number: 20060240034
    Abstract: The invention concerns a vaccine that can induce protection against disease especially in consequence of a lentivirus infection, especially an infection with the Feline Leukosis virus. Such vaccine comprises codon-optimized DNA sequences encoding structural proteins and the most important membrane protein of FeLV.
    Type: Application
    Filed: September 23, 2002
    Publication date: October 26, 2006
    Inventors: Claas Junghans, Matthias Schroff, Christiane Juhls, Vierte Oswald, Hans Lutz
  • Patent number: 7074772
    Abstract: The invention concerns an expressible nucleic acid construct, which contains only the sequence information necessary for expressing a gene for RNA or protein synthesis. Expression constructs of this type can be used in gene therapy and genetic vaccination and avoid many of the risks associated with constructs today. The invention further concerns the possibility of improving the conveying of the construct into cells or tissue by covalent linkage of the construct, for example to particles of peptides.
    Type: Grant
    Filed: August 27, 2002
    Date of Patent: July 11, 2006
    Assignee: Mologen AG
    Inventors: Burghardt Wittig, Claas Junghans
  • Patent number: 6849725
    Abstract: Short deoxyribonucleic acid molecules that are partially single-stranded, dumbbell-shaped, and covalently closed, which contain one or more unmethylated cytosine guanosine motif (CpG motif) and exhibit immunomodifying effects. Such molecules can be used for immunostimulation applications in humans or vertebrates.
    Type: Grant
    Filed: January 24, 2002
    Date of Patent: February 1, 2005
    Assignee: Mologen Forschungs Entwicklungs und Vertriebs GmbH
    Inventors: Claas Junghans, Burghardt Wittig, Sven König Merediz, Matthias Schroff
  • Publication number: 20040138115
    Abstract: A remedy to suppress the sensation of pain, especially in chronic inflammatory diseases, by means of expressing endogenous neuroendocrine peptides at the site of inflammation. In particular, the invention relates to the expression of POMC or CRF from locally injected DNA expression constructs, preferably covalently peptide-modified expression constructs.
    Type: Application
    Filed: August 22, 2003
    Publication date: July 15, 2004
    Inventors: Burghardt Wittig, Christoph Stein, Michael Schafer, Matthias Schroff, Claas Junghans, Sven Andres Konig Merediz
  • Publication number: 20030125279
    Abstract: Short deoxyribonucleic acid molecules that are partially single-stranded, dumbbell-shaped, and covalently closed, which contain one or more unmethylated cytosine guanosine motif (CpG motif) and exhibit immunomodifying effects. Such molecules can be used for immunostimulation applications in humans or vertebrates.
    Type: Application
    Filed: January 24, 2002
    Publication date: July 3, 2003
    Inventors: Claas Junghans, Burghardt Wittig, Sven Konig Merediz, Matthias Schroff
  • Publication number: 20030054392
    Abstract: The invention concerns an expressible nucleic acid construct, which contains only the sequence information necessary for expressing a gene for RNA or protein synthesis. Expression constructs of this type can be used in gene therapy and genetic vaccination and avoid many of the risks associated with constructs today. The invention further concerns the possibility of improving the conveying of the construct into cells or tissue by covalent linkage of the construct, for example to particles of peptides.
    Type: Application
    Filed: August 27, 2002
    Publication date: March 20, 2003
    Applicant: SOFT GENE GMBH
    Inventors: Burghardt Wittig, Claas Junghans
  • Patent number: 6451593
    Abstract: The invention concerns an expressible nucleic acid construct, which contains only the sequence information necessary for expressing a gene for RNA or protein synthesis. Expression constructs of this type can be used in gene therapy and genetic vaccination and avoid many of the risks associated with constructs today. The invention further concerns the possibility of improving the conveying of the construct into cells or tissue by covalent linkage of the construct, for example to particles or peptides.
    Type: Grant
    Filed: May 12, 1999
    Date of Patent: September 17, 2002
    Assignee: Soft Gene GmbH
    Inventors: Burghardt Wittig, Claas Junghans
  • Patent number: 6451563
    Abstract: A process to obtain linear double-stranded covalently closed DNA “dumbbell” constructs from plasmids by restriction digest, subsequent ligation with hairpin oligodesoxyribonucleotides, optionally in the presence of restriction enzyme, and a final digestion with endo- and exonucleolytic enzymes that degrade all contaminating polymeric DNA molecules but the desired construct. The invention also provides a process to obtain said dumbbell constructs employing endonuclease class II enzymes. Furthermore, the invention provides a process to obtain linear, covalently closed DNA molecules, such as plasmids, free from contamination by genomic DNA, by submitting the DNA preparation to a facultative endonucleolytic degradation step and an obligatory exonucleolytic degradation step.
    Type: Grant
    Filed: February 14, 2000
    Date of Patent: September 17, 2002
    Assignee: Mologen Forschungs-, Entwicklungs- und Vertriebs GmbH
    Inventors: Burghardt Wittig, Claas Junghans, Matthias Schroff
  • Patent number: 5334328
    Abstract: Azetidinones of the formula I ##STR1## in which, for example, R.sup.1 is an alkyl or alkenyl radical, R.sup.2 and R.sup.3 are hydrogen or an alkyl or alkenyl radical, Z is hydrogen or (pseudo)halogen, A.sup.1, A.sup.2 and A.sup.3 are a ring system, and M is a spacer group, can be added to liquid-crystal mixtures. Even when admixed in small amounts, they cause considerable twist in the cholesteric and smectic C* phase, which can compensate the pitch of another dope or produce a short S.sub.C * pitch.
    Type: Grant
    Filed: June 17, 1992
    Date of Patent: August 2, 1994
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Gunter Scherowsky, Claas Junghans, Anke Kaltbeitzel, Rainer Wingen, Britta Michalski